Thursday 16 October, 2025
Background: In vitro time-kill models offer a platform for studying antibiotic PKPD, potentially translatable to in vivo effects via PKPD…
Read moreAbstracts
A pharmacometric model on cytokine changes upon live Escherichia coli exposure in a porcine sepsis model
Thursday 16 October, 2025
Objectives: Effective sepsis management is challenged by sepsis heterogeneity and the lack of clear understanding of the time course of…
Read moreCeralasertib-induced haematological toxicity modelling to support monotherapy Recommended Phase 2 Dose determination
Thursday 16 October, 2025
Objectives: Ceralasertib (AZD6738) is an inhibitor of the ATR protein kinase, the apical kinase in the replication stress response DNA-damage induced…
Read moreA Long-Short Term Memory Approach to Predicting Neutrophil Count in Patients Undergoing Drug Treatment
Thursday 16 October, 2025
Objectives: Neutropenia is a common dose-limiting toxicity in oncology patients following chemotherapy or targeted therapies. The Friberg PKPD model [1]…
Read morePharmpy: a versatile open-source library for pharmacometrics
Thursday 16 October, 2025
The development of pharmacometric nonlinear mixed effect models is a complex, multi-step process. Generally, it begins with an informed starting…
Read morePharmpy: a versatile open-source software package for pharmacometrics
Thursday 16 October, 2025
The development of pharmacometric models is a complex, multi-step process. Generally, it begins with an informed starting model, which is…
Read moreDeepCIM: Prediction of myelosuppressive anti-cancer molecules using drug-target interaction datasets
Thursday 16 October, 2025
Objectives: The accurate modelling and analysis of chemotherapy-induced myelosuppression (CIM) in preclinical development are crucial for understanding the potential therapeutic…
Read morePharmacometric analysis to explore moxidectin treatment with and without albendazole in Trichuris trichiura-infected adolescents
Thursday 16 October, 2025
Introduction: Moxidectin is a promising drug candidate that has the potential to complement the depleted drug arsenal against infections with…
Read moreEnhanced pharmacometrics model utilizes heart rate to monitor thyroid function in pediatric Graves’ disease under pharmacotherapy
Thursday 16 October, 2025
Objectives: Graves’ disease (GD) with onset in childhood or adolescence is a serious pediatric rare disease (ORPHA:525731). Leading clinical signs…
Read moreAssessment of sensitivity and specificity in the context of pharmacometrics-based decision support tools: application to hyperbilirubinemia in neonates
Thursday 16 October, 2025
Introduction: Clinical decision support systems are becoming increasingly important in daily clinical practice. Most current tools are designed for diagnosis…
Read more